Lung Cancer Treatment Market Size & Growth Forecast 2027–2036, By Segments (Therapy, Type, End-user), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Lung Cancer Treatment Market size was worth USD 23.44 Billion in 2026 and is expected to grow at 12.9% CAGR between 2027 and 2036, reaching USD 78.87 Billion by 2036. The industry revenue for 2027 is calculated at USD 26.06 Billion.

• Base Year Value (2026): USD 23.44 Billion
• CAGR (2027-2036): 12.9%
• Forecast Year Value (2036): USD 78.87 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Lung Cancer Treatment Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led in 2025 through advanced oncology infrastructure, strong diagnostics, broad access to specialized therapies, and continued investment in cancer research and precision medicine.
  • Asia Pacific is growing fastest as cancer incidence rises, healthcare infrastructure improves, and access to screening, specialized cancer centers, and modern therapies expands.

• Segment Momentum:

  • Targeted therapy dominated with a 39.53% share in 2025 due to precision medicine adoption, biomarker testing expansion, and improved patient selection through molecular diagnostics.
  • Immunotherapy is expanding rapidly through increasing clinical adoption, broader indications, and combination treatment strategies that support personalized oncology care and improved treatment outcomes.

• Market Expansion Drivers:

  • Increasing global lung cancer prevalence driving sustained demand for advanced oncology treatments
  • Rising tobacco consumption and air pollution accelerating lung cancer incidence rates globally
  • Expanding reimbursement coverage improving patient access to high-cost targeted therapies and immunotherapy

• Leading Market Participants:

  Prominent companies in the lung cancer treatment market include AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Bristol Myers Squibb Company (United States), Roche Holding AG (Switzerland), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Johnson & Johnson (United States), GlaxoSmithKline plc (United Kingdom), Sanofi S.A. (France)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 23.44 Billion
  • 2027 Estimated Market Size: USD 26.06 Billion
  • Projected Market Size: USD 78.87 Billion by 2036
  • Growth Forecasts: 12.9% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Targeted Therapy (Therapy) | Non-small Cell Lung Cancer (Type) | Hospitals (End-user)
  • Emerging Opportunity Segment: Immunotherapy (Therapy) | Non-small Cell Lung Cancer (Type) | Specialty Clinics (End-user)

Market Growth Drivers and Industry Trends

Increasing global lung cancer prevalence driving sustained demand for advanced oncology treatments

The growing burden of lung cancer across both developed and emerging economies is creating sustained demand for innovative therapeutic approaches, and this trend will drive the lung cancer treatment market growth. Rising diagnosis rates are encouraging greater utilization of targeted therapies, immunotherapies, chemotherapy, and combination treatment regimens that improve disease management across different stages of cancer. Healthcare providers are also expanding multidisciplinary treatment strategies that integrate advanced diagnostics with personalized therapeutic planning to achieve more effective clinical outcomes for patients.

Rising tobacco consumption and air pollution accelerating lung cancer incidence rates globally

Increasing exposure to tobacco use and environmental pollutants continues to elevate the global incidence of lung cancer, and the lung cancer treatment market is benefiting from the resulting need for long-term disease management. Persistent risk factors contribute to a larger patient population requiring early diagnosis, continuous monitoring, and comprehensive therapeutic intervention. As healthcare systems respond to the growing clinical burden, demand is increasing for a broad range of oncology treatments that address diverse disease subtypes and varying stages of progression.

Expanding reimbursement coverage improving patient access to high-cost targeted therapies and immunotherapy

Broader reimbursement policies are improving affordability for advanced oncology treatments, a development that will propel the lung cancer treatment market growth by increasing patient access to innovative therapies. Expanded insurance coverage reduces financial barriers associated with targeted therapies and immunotherapy, enabling healthcare providers to recommend more effective treatment options based on clinical suitability rather than cost considerations. Improved reimbursement frameworks also support wider adoption of personalized treatment protocols across hospitals, specialty clinics, and oncology care networks.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing global lung cancer prevalence driving sustained demand for advanced oncology treatments	2.7%	High	North America, Europe, Asia Pacific	High	Near Term
Rising tobacco consumption and air pollution accelerating lung cancer incidence rates globally	2.3%	High	Asia Pacific, Europe, North America	High	Near Term
Expanding reimbursement coverage improving patient access to high-cost targeted therapies and immunotherapy	2%	High	North America, Europe	High	Near Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

The lung cancer treatment market was led by North America in 2026, reflecting the region's advanced oncology infrastructure, strong diagnostic capabilities, and broad access to sophisticated treatment approaches. High awareness of lung cancer screening and increasing emphasis on early detection support the identification and management of patients at earlier stages, while established healthcare systems facilitate access to targeted therapies, immunotherapies, radiation treatment, and other specialized interventions. Continued investment in cancer research and precision medicine is further strengthening the region's treatment landscape.

Asia Pacific is projected to experience the fastest growth, supported by rising cancer incidence, improving healthcare infrastructure, and expanding access to modern oncology therapies. Greater awareness of cancer screening and diagnosis is encouraging earlier patient engagement, while healthcare investments are improving treatment capacity in developing markets. The expansion of specialized cancer centers, increasing adoption of precision-based treatment, and efforts to improve affordability and availability of advanced therapies are expected to further strengthen regional demand.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Therapy Segment Analysis: Targeted Therapy (Largest Segment) vs Immunotherapy (Fastest-Growing Segment)

The targeted therapy segment dominated the lung cancer treatment market, accounting for the largest share of 39.53% in 2026. Its leading position is driven by the increasing use of precision medicine approaches that target specific genetic mutations associated with lung cancer. Advances in molecular diagnostics have enabled more accurate patient selection, allowing targeted therapies to improve treatment effectiveness while reducing damage to healthy tissues. Continued expansion of biomarker testing and personalized treatment strategies further strengthens the segment's leadership.

The immunotherapy segment is expected to witness the fastest growth as immune-based treatment approaches become increasingly integrated into lung cancer management. Growing clinical adoption, expanding indications, and ongoing advances in immune checkpoint therapies are improving treatment outcomes for eligible patients. Increased emphasis on combination treatment strategies and personalized oncology care continues to support rapid expansion of this therapy segment.

Type Segment Analysis: Non-small Cell Lung Cancer (Largest & Fastest-Growing Segment)

The non-small cell lung cancer segment led the lung cancer treatment market and held the largest share in 2026. Its dominance is supported by the substantial clinical burden of this disease type and the broad availability of treatment options, including targeted therapies, immunotherapies, chemotherapy, radiation therapy, and surgical interventions. Continuous advancements in molecular profiling, early diagnosis, and personalized treatment protocols have significantly expanded therapeutic opportunities for patients. Ongoing research into novel oncology treatments and increasing adoption of precision medicine continue to position the non-small cell lung cancer segment as both the largest and fastest-growing disease type.

End-user Segment Analysis: Hospitals (Largest Segment) vs Specialty Clinics (Fastest-Growing Segment)

The hospitals segment held the largest share in 2026 due to their comprehensive oncology infrastructure, multidisciplinary treatment teams, and access to advanced diagnostic and therapeutic technologies. Hospitals remain the primary centers for managing complex lung cancer cases, offering integrated services ranging from diagnosis and surgery to systemic therapies and supportive care. Their ability to deliver coordinated treatment across multiple specialties reinforces their dominant position.

The specialty clinics segment is emerging as the fastest-growing end-user owing to increasing demand for specialized oncology services, personalized treatment planning, and outpatient cancer care. These facilities are expanding access to advanced therapies while offering focused clinical expertise, shorter waiting times, and greater convenience for patients requiring ongoing treatment and follow-up care.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Therapy	Radiation Therapy, Immunotherapy, Targeted Therapy, Chemotherapy, Others	Targeted Therapy	Immunotherapy
Type	Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid	Non-small Cell Lung Cancer	Non-small Cell Lung Cancer
End-user	Hospitals, Specialty Clinics, Homecare, Others	Hospitals	Specialty Clinics

Competitive Landscape and Market Positioning

Top players in the lung cancer treatment market:

1. AstraZeneca plc (United Kingdom)
2. Pfizer, Inc. (United States)
3. Merck & Co., Inc. (United States)
4. Bristol Myers Squibb Company (United States)
5. Roche Holding AG (Switzerland)
6. Novartis AG (Switzerland)
7. Takeda Pharmaceutical Company Limited (Japan)
8. Johnson & Johnson (United States)
9. GlaxoSmithKline plc (United Kingdom)
10. Sanofi S.A. (France)

Lung cancer treatment providers are competing around advances in precision medicine, therapy personalization, and improved patient outcomes as treatment approaches become increasingly targeted. Companies with capabilities in biomarker-driven therapies, diagnostic integration, and combination treatment strategies are strengthening their positions as clinicians move away from one-size-fits-all approaches. Competition is also intensifying among developers seeking to address unmet needs across different disease stages, with differentiation increasingly tied to clinical effectiveness, safety profiles, and adaptability within evolving care pathways. The market continues to shift toward platforms that connect diagnosis and treatment decisions more closely, creating opportunities for participants that can support comprehensive oncology management.

Industry Development/News

Company Name	Date	Key Development
Roche	May-26	Roche introduced the subcutaneous formulation of Tecentriq in India for lung cancer management, offering a streamlined administration method designed to decrease hospital visit durations and elevate patient convenience while broadening access to immunotherapy.
Amgen Korea	Apr-26	Amgen Korea scaled its BiTE platform capabilities into solid tumors by progressing Imdelltra for small cell lung cancer, diversifying its oncology asset base away from hematologic malignancies via bispecific T-cell engager technology.
Incyte	Feb-26	The U.S. FDA delivered a Complete Response Letter regarding the retifanlimab and chemotherapy combination application in metastatic non-small cell lung cancer, driven by regulatory compliance findings at a contracted third-party manufacturing site.
ImmunityBio	Jan-26	ImmunityBio secured conditional approval from Saudi Arabia for Anktiva targeting advanced non-small cell lung cancer, representing the inaugural regulatory clearance for the therapy within this specific clinical indication.
CorriXR Therapeutics	Dec-25	CorriXR Therapeutics established a strategic partnership alongside InhaTarget Therapeutics and Merxin Ltd to engineer an inhaled CRISPR-based genetic treatment for lung cancer, integrating advanced gene-editing platforms with specialized pulmonary delivery and inhalation systems.
AbbVie	Dec-25	AbbVie secured global rights to the small cell lung cancer candidate alveltamig through an agreement valued at up to $1.07 billion, which included an initial upfront payment of $100 million to expand its pipeline via strategic licensing.
Royalty Pharma	Sep-25	Royalty Pharma completed a transaction worth up to $950 million to acquire royalty interests tied to Amgen's Imdelltra, expanding its investment footprint in targeted therapeutics designed for small cell lung cancer.
Yuhan Corporation	Aug-25	Yuhan Corporation attained regulatory authorization in China for Lazcluze, a therapy licensed to Johnson & Johnson, which activated a $45 million milestone payment and extended the product footprint into a major global pharmaceutical market.